GSK - GlaxoSmithKline plc

NYSE - Nasdaq Real-time price. Currency in USD
43.21
+0.69 (+1.61%)
As of 2:23PM EDT. Market open.
Stock chart is not supported by your current browser
Previous close42.52
Open43.10
Bid43.17 x 800
Ask43.18 x 1800
Day's range42.96 - 43.31
52-week range36.41 - 43.31
Volume2,556,363
Avg. volume2,275,766
Market cap106.423B
Beta (3Y monthly)0.52
PE ratio (TTM)43.55
EPS (TTM)0.99
Earnings date1 Feb 2017 - 6 Feb 2017
Forward dividend & yield1.86 (4.41%)
Ex-dividend date2019-08-08
1y target est46.25
Trade prices are not sourced from all markets
  • Is a Beat in Store for Glaxo (GSK) This Earnings Season?
    Zacks

    Is a Beat in Store for Glaxo (GSK) This Earnings Season?

    Glaxo's (GSK) Vaccines and Respiratory segments are likely to have driven sales growth in the third quarter.

  • Lilly (LLY) Q3 Earnings Top Estimates, Sales Lag, Stock Down
    Zacks

    Lilly (LLY) Q3 Earnings Top Estimates, Sales Lag, Stock Down

    Eli Lilly's (LLY) Q3 earnings beat estimates while sales miss. Shares drop in pre-market trading.

  • 5 High-Flying Corporate Giants Set to Beat on Q3 Earnings
    Zacks

    5 High-Flying Corporate Giants Set to Beat on Q3 Earnings

    Despite almost day-to-day market fluctuations, a few corporate behemoths surged in Wall Street. Some of these are set to beat earnings estimate in the ongoing reporting cycle.

  • Novartis (NVS) Q3 Earnings & Sales Beat Estimates, Up Y/Y
    Zacks

    Novartis (NVS) Q3 Earnings & Sales Beat Estimates, Up Y/Y

    Novartis (NVS) beats sales estimates in the third quarter of 2019, driven by robust performance of key drugs and increased contribution from new launches.

  • What's in the Cards for Sarepta (SRPT) This Earnings Season?
    Zacks

    What's in the Cards for Sarepta (SRPT) This Earnings Season?

    Sarepta Therapeutics' (SRPT) third-quarter results are expected to reflect the impact of strong demand for Exondys 51. Regulatory update related to golodirsen is what investors are expected be focused on.

  • Top Research Reports for Walmart, AstraZeneca & Broadcom
    Zacks

    Top Research Reports for Walmart, AstraZeneca & Broadcom

    Top Research Reports for Walmart, AstraZeneca & Broadcom

  • What's in the Cards for AstraZeneca (AZN) in Q3 Earnings?
    Zacks

    What's in the Cards for AstraZeneca (AZN) in Q3 Earnings?

    AstraZeneca's (AZN) third-quarter result is expected to reflect the impact of new drug sales.

  • GSK to sell two vaccines in $1.1 billion deal to focus on newer treatments
    Reuters

    GSK to sell two vaccines in $1.1 billion deal to focus on newer treatments

    The sale of anti-rabies treatment Rabipur and Encepur, used for the prevention of tick-borne encephalitis, to the Denmark-based biotechnology firm includes an upfront payment of 301 million euros and milestone payments of up to 495 million euros. Chief Executive Officer Emma Walmsley has been pushing for a leaner structure since she took over in 2017 by spinning off or selling units to focus on reinvigorating GSK's pharmaceuticals business. It staged a comeback into cancer treatments with a $5.1 billion buyout of U.S. drugmaker Tesaro in December last year.

  • AstraZeneca's Breast Cancer Candidate BLA Gets Priority Review
    Zacks

    AstraZeneca's Breast Cancer Candidate BLA Gets Priority Review

    AstraZeneca (AZN) announces acceptance of BLA seeking approval for trastuzumab deruxtecan in metastatic breast cancer by the FDA. The FDA also grants priority review.

  • Novartis' Jakavi Meets Primary Goal in Phase III for GVHD
    Zacks

    Novartis' Jakavi Meets Primary Goal in Phase III for GVHD

    Novartis' (NVS) phase III REACH2 study on Jakavi for treating patients with steroid-refractory acute graft-versus-host disease meets the primary endpoint of superior overall response rate.

  • Can the GlaxoSmithKline (GSK) share price double your money?
    Fool.co.uk

    Can the GlaxoSmithKline (GSK) share price double your money?

    Buying GlaxoSmithKline (LSE: GSK) and reinvesting your dividends can build real wealth over time.

  • Reuters - UK Focus

    Teva's UK arm recalls some batches of Ranitidine - Medicines watchdog

    Teva Pharmaceutical's UK unit has recalled some batches of heartburn medicine Ranitidine, Britain's medicines watchdog said on Thursday, making it the latest drugmaker to pull the product. Teva, the world's largest generic drugmaker, is recalling all unexpired stock of Ranitidine Effervescent Tablets in 150 micrograms and 300 micrograms dosages, the Medicines and Healthcare products Regulatory Agency (MHRA) said https://www.gov.uk/government/news/ranitidine-mhra-drug-alert-issued-for-teva-uk-recall. Teva did not immediately respond to a request for comment.

  • Should Value Investors Buy GlaxoSmithKline (GSK) Stock?
    Zacks

    Should Value Investors Buy GlaxoSmithKline (GSK) Stock?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • Is GlaxoSmithKline plc (GSK) Outperforming Other Medical Stocks This Year?
    Zacks

    Is GlaxoSmithKline plc (GSK) Outperforming Other Medical Stocks This Year?

    Is (GSK) Outperforming Other Medical Stocks This Year?

  • Digging in to the Glaxosmithkline dividend payment (LON:GSK)
    Stockopedia

    Digging in to the Glaxosmithkline dividend payment (LON:GSK)

    Glaxosmithkline (LON:GSK) is a global healthcare company that pays out an attractive rolling dividend yield of 4.75%. I'd like to know how safe Glaxosmithklin8230;

  • The Zacks Analyst Blog Highlights: Novartis, J&J, Pfizer, Novo Nordisk and Glaxo
    Zacks

    The Zacks Analyst Blog Highlights: Novartis, J&J, Pfizer, Novo Nordisk and Glaxo

    The Zacks Analyst Blog Highlights: Novartis, J&J, Pfizer, Novo Nordisk and Glaxo

  • Forget the Cash ISA! I believe these FTSE 100 dividend stocks are a much better buy
    Fool.co.uk

    Forget the Cash ISA! I believe these FTSE 100 dividend stocks are a much better buy

    Why I think these steady FTSE 100 (INDEXFTSE: UKX) dividend-paying shares could power your compounding retirement savings.

  • Emergent's Chikungunya Vaccine Candidate Gets EMA's PRIME Tag
    Zacks

    Emergent's Chikungunya Vaccine Candidate Gets EMA's PRIME Tag

    Emergent's (EBS) chikungunya vaccine candidate CHIKV VLP gains the PRIME status from the Committee for Medicinal Products for Human Use in Europe.

  • Pharma Stock Roundup: NVS' New Eye Drug Gets FDA Nod, NVO, GSK, PFE Sign Deals
    Zacks

    Pharma Stock Roundup: NVS' New Eye Drug Gets FDA Nod, NVO, GSK, PFE Sign Deals

    FDA approves Novartis' (NVS) Beovu. J&J (JNJ) files sBLA for Stelara. Pfizer (PFE), Novo Nordisk (NVO) and Glaxo (GSK) announce collaboration deals.

  • Here’s why I think you can retire on the GSK share price
    Fool.co.uk

    Here’s why I think you can retire on the GSK share price

    The GSK share price offers the perfect combination of a steady dividend income and the potential for long-term growth, explains Rupert Hargreaves.

  • Reuters - UK Focus

    UPDATE 1-British blue-chips trail Europe as Brexit deal hopes lift pound

    London's exporter-laden FTSE 100 lagged its European peers on Wednesday, as sterling gained on a report that the EU was ready to make a "major concession" on the Brexit divorce deal, while Just Eat helped the index hold on to slim gains. The blue-chip index, whose components make two-thirds of their earnings abroad, was slightly off the day's highs but was still up 0.1% by 0858 GMT, while the FTSE 250 was down 0.1%. Just Eat climbed 2% to top the FTSE 100 leader-board, after its Dutch rival Takeaway.com reported a surge in quarterly orders.

  • Reuters - UK Focus

    UPDATE 3-GSK recalls popular heartburn drug Zantac globally after cancer scare

    GlaxoSmithKline on Tuesday said it is recalling the popular heartburn medicine Zantac in all markets as a "precaution", days after the U.S. Food and Drug Administration found "unacceptable" levels of probable cancer-causing impurity in the drug. Zantac, also sold generically as ranitidine, is the latest drug in which cancer-causing impurities have been found. Britain's medicines watchdog said GlaxoSmithKline (GSK) was recalling four prescription-only Zantac medicines: a syrup, an injection and tablets of 150 and 300 milligram (mg) dosages.

  • GSK recalls popular heartburn drug Zantac globally after cancer scare
    Reuters

    GSK recalls popular heartburn drug Zantac globally after cancer scare

    Zantac, also sold generically as ranitidine, is the latest drug in which cancer-causing impurities have been found. Britain's medicines watchdog said GlaxoSmithKline (GSK) was recalling four prescription-only Zantac medicines: a syrup, an injection and tablets of 150 and 300 milligram (mg) dosages. Over-the-counter 75 mg dosage Zantac products are produced by a different company and are not affected by the recall, it added.

  • Emergent's Vaccine Profile Boosts Sales Despite Stiff Rivalry
    Zacks

    Emergent's Vaccine Profile Boosts Sales Despite Stiff Rivalry

    Emergent's (EBS) vaccine portfolio holds great potential with the newly-acquired Narcan nasal spray progressing well. Severe rivalry remains a concern though.

  • Bloomberg

    Trio Wins Nobel for Oxygen Studies That Led to Anemia Drugs

    (Bloomberg) -- Three researchers from the U.S. and Britain won a Nobel Prize for showing how cells sense and adapt to changing oxygen levels, a line of research that’s already led to the development of new drugs.Americans William Kaelin of the Dana-Farber Cancer Institute in Boston and Gregg Semenza of Baltimore’s Johns Hopkins Medicine, and Peter Ratcliffe of the Francis Crick Institute in London received this year’s award for physiology or medicine, the Nobel Assembly at the Karolinska Institute said Monday in a statement.“The seminal discoveries by this year’s Nobel laureates revealed the mechanism for one of life’s most essential adaptive processes,” the assembly said in the statement. “Their discoveries have also paved the way for promising new strategies to fight anemia, cancer and many other diseases.”Semenza and Ratcliffe separately studied the processes surrounding the sensing of oxygen, and found it was at work in virtually all the body’s tissues. Semenza worked in the 1990s on identifying a protein complex that binds to cells’ DNA in response to levels of oxygen in the environment.The complex, called hypoxia inducible factor, regulates production of red blood cells. The science behind it is the basis for an anemia drug codeveloped by AstraZeneca Plc and Fibrogen Inc. called roxadustat that was approved in China in December.Astra is just a few steps away from bringing the drug to patients, said Mene Pangalos, executive vice president of biopharmaceutical research and development, in an email. “This would never have been possible without early breakthroughs of this year’s Nobel winners,” he said.GlaxoSmithKline Plc has filed for Japanese approval of a drug based on the mechanism, called daprodustat. Kaelin’s work linked the same oxygen-regulating machinery to a role in cancer, which is also being mined for potential therapeutics.Annual prizes for achievements in physics, chemistry, medicine, peace and literature were established in the will of Alfred Nobel, the Swedish inventor of dynamite, who died in 1896. The total amount for each of the 2019 prizes is 9 million kronor ($909,000).(Updates with company comment in sixth paragraph)\--With assistance from John Lauerman.To contact the reporters on this story: Niklas Magnusson in Stockholm at nmagnusson1@bloomberg.net;Veronica Ek in Stockholm at vek@bloomberg.netTo contact the editors responsible for this story: Jonas Bergman at jbergman@bloomberg.net, ;Tasneem Hanfi Brögger at tbrogger@bloomberg.net, Eric PfannerFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more